Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Metastatic Disease
Increasing Epirubicin Dosing Significantly Decreases Metastatic Breast Cancer Pain
May 6th, 2000
For patients with metastatic breast cancer undergoing the FEC drug regimen (5-fluorouracil, epirubicin, and cyclophosphamide), doubling the dose intensity of the epirubicin (EPI) component can have a significant positive effect on pain and self-image, say researchers. "From May 1995 [to May 1997], 74 consecutive patients with MBC were randomly treated with six courses of two FEC regimens containing 60 (60FEC) or 120 (120FEC, supported by primary G-CSF) mg/m(2) of EPI," explained A. Riccardi and colleagues in Italy ("Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: A prospective, randomized, multicentric study on...
Source: Women's Health Weekly (2000-05-06)
|
